Rahko’s Co-founder and former VP of AI at Odyssey Therapeutics will lead the technical growth of LabGenius’ ML-driven drug discovery platform LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use ...
At an old biscuit factory in South London, giant mixers and industrial ovens have been replaced by robotic arms, incubators, and DNA sequencing machines. James Field and his company LabGenius aren’t ...
LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) Annual 2023 Meeting ...
LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use of machine learning (ML) for protein engineering, today announced the signing of a multi-year research collaboration with Ablynx, a Sanofi ...
Prominent oncology clinician Prof Hendrik-Tobias Arkenau and computational antibody design expert Prof Victor Greiff will bolster LabGenius’ leadership in the field of machine learning-driven antibody ...
LONDON, December 04, 2025--(BUSINESS WIRE)--LabGenius Therapeutics ("LabGenius"), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential ...
For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA™, was used to discover and concomitantly optimise a TCE with improved killing ...
LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding. The round is led by Lux Capital and Obvious Ventures, with ...
Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVA TM, to the optimization of therapeutic NANOBODY ® proteins LONDON–(BUSINESS WIRE)–July 15, 2021– ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results